

VEGF3 Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP11951A

Product Information

Application	WB, IHC-P, FC, E
Primary Accession	P49767
Other Accession	NP_005420
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB11713
Calculated MW	46883
Antigen Region	20-49

Additional Information

Gene ID	7424
Other Names	Vascular endothelial growth factor C, VEGF-C, Flt4 ligand, Flt4-L, Vascular endothelial growth factor-related protein, VRP, VEGFC
Target/Specificity	This VEGF3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 20-49 amino acids from the N-terminal region of human VEGF3.
Dilution	WB~~1:1000 IHC-P~~1:100~500 FC~~1:10~50 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	VEGF3 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	VEGFC
Function	Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the

permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.

Cellular Location

Secreted.

Tissue Location

Expressed in the spleen (PubMed:8700872, PubMed:9247316). Expressed in the lymph node, thymus, appendix and bone marrow (PubMed:9247316). Expressed in the heart, placenta, skeletal muscle, ovary and small intestine (PubMed:8617204, PubMed:8700872) Expressed in the prostate, testis and colon (PubMed:8700872)


Background

The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D. [provided by RefSeq].


References

Chen, X., et al. Cancer Sci. 101(11):2384-2390(2010)
 Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :
 Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
 Deguchi, K., et al. Anticancer Res. 30(6):2361-2366(2010)
 Johnatty, S.E., et al. PLoS Genet. 6 (7), E1001016 (2010) :


Images




Anti-VEGF3 Antibody (N-term) at 1:1000 dilution + K562 whole cell lysates/ proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 47 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



VEGF3 Antibody (N-term) (Cat. #AP11951a) western blot analysis in MCF-7 cell line lysates (35ug/lane). This demonstrates the VEGF3 antibody detected the VEGF3 protein (arrow).



VEGF3 Antibody (N-term) (Cat. #AP11951a) immunohistochemistry analysis in formalin fixed and paraffin embedded human skeletal muscle followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of VEGF3 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.



VEGF3 Antibody (N-term) (Cat. #AP11951a) flow cytometric analysis of MCF-7 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.